October 9, 2026 · Science & Research Daily Digest
A digest of science, space, biomedicine, and climate research for October 9, 2026, with summaries, links, and commentary.
I. Spaceflight and Low Earth Orbit
1. Cygnus XL is released from the robotic arm at 12:44 p.m. EDT, ending CRS-24 (Low Earth orbit)
Summary:
NASA's station blog says Northrop Grumman's Cygnus XL was released from the Canadarm2 robotic arm at 12:44 p.m. EDT on October 9, after it had been detached from the Earth-facing port of the Unity module. At release, the station was about 260 miles above the Pacific Ocean. The post-release note says the spacecraft left nearly six months after arriving with about 11,000 pounds of supplies, investigations, commercial products, and hardware. Controllers will command a deorbit on Monday, October 12, carrying several thousand pounds of disposal cargo to a destructive re-entry; NASA will not cover the deorbit. An earlier blog the same day had set re-entry for Sunday, October 11. That note also says the vehicle launched on April 11 aboard a Falcon 9 from Cape Canaveral's SLC-40, was installed at Unity on April 13, and was monitored by NASA astronaut Luke Delaney, with release planned for about 12:43 p.m.
Links:
- NASA — Cygnus XL Cargo Spacecraft Released from Station by Canadarm2
- NASA — Cygnus XL Cargo Spacecraft Departing Station Soon on NASA+
Commentary:
What is fixed today is the release time and a rewritten re-entry date, not a catalogue of the experiments flown during the six months.
2. NASA issues the final commercial low-Earth-orbit station solicitation, with proposals due December 8 (Commercial spaceflight)
Summary:
The NASA release page was updated at 14:11 EDT on October 9, 2026. The text says that on Friday the agency issued its final Request for Proposals for the next generation of commercial space stations. Administrator Jared Isaacman said the United States will still need a place for research, technology development, crew training, and preparation for the Moon and Mars after the International Space Station retires. The release recalls two Requests for Information in March, a draft Request for Proposals in July, and a later industry day plus one-on-one meetings. Proposals are due Tuesday, December 8, with awards expected in spring 2027. NASA intends to award firm-fixed-price, multi-award, indefinite-delivery/indefinite-quantity contracts, select two or more contractors through early development, and then use a competitive task order for final design, test, evaluation, certification, and services from one or more contractors. The scope is commercial low-Earth-orbit destinations that can provide end-to-end destination and transportation services for human spaceflight.
Links:
Commentary:
Friday produced a procurement document and a December 8 deadline, not a chosen successor to the space station.
II. Biomedicine
3. FDA approves atezolizumab plus chemotherapy as adjuvant treatment for stage III dMMR colon cancer (Oncology)
Summary:
The FDA drug page dates the approval to October 8, 2026: atezolizumab (Tecentriq, Genentech) with a fluoropyrimidine and oxaliplatin for adjuvant treatment of patients two years and older with stage III mismatch-repair-deficient colon cancer, and subcutaneous Tecentriq Hybreza for patients 12 and older who weigh at least 40 kilograms. The basis is ATOMIC/ML39057 (NCT02912559). After complete resection with no residual nodal or metastatic disease, 711 adults and one child were randomized 1:1 to atezolizumab plus mFOLFOX6 for 12 cycles followed by six months of atezolizumab alone, or to mFOLFOX6 alone for 12 cycles. Investigator-assessed disease-free survival had a hazard ratio of 0.50 (95% confidence interval 0.35 to 0.73; p-value 0.0001). Median disease-free survival was not reached in either arm. The review used Project Orbis with Australia's TGA, Health Canada, Israel's Ministry of Health, and Swissmedic; those reviews are ongoing, and the applications received priority review. Roche announced the same approval from Basel on October 9, called it Tecentriq's twelfth U.S. indication, and cited the ATOMIC paper in The New England Journal of Medicine: 36-month disease-free survival of 86% versus 76%, a 50% reduction in the risk of recurrence or death.
Links:
- FDA — Atezolizumab with chemotherapy for stage III dMMR colon cancer
- Roche — FDA approves Tecentriq combination for stage III dMMR colon cancer
Commentary:
The hazard ratio of 0.50 comes from an adjuvant trial in which median disease-free survival has not been reached in either arm, and the parallel reviews in four other countries are still open.
4. FDA approves once-monthly subcutaneous olanzapine, WELTRUZA, for adults with schizophrenia (Psychiatry)
Summary:
Teva announced on October 9 that the FDA has approved WELTRUZA (olanzapine) extended-release injectable suspension for schizophrenia in adults, as a once-monthly subcutaneous injection. The company says it requires no loading dose, no oral supplementation, and no post-injection monitoring. The strengths are 318 mg, 425 mg, and 531 mg, corresponding to daily oral olanzapine of 10 mg, 15 mg, and 20 mg. The basis is phase 3 SOLARIS. In the first eight weeks, 675 patients were randomized 1:1:1:1 to low, medium, or high dose or placebo; a 48-week second period assessed safety and tolerability. The primary endpoint was PANSS, with CGI-S and PSP among the key secondary endpoints. The release says the three doses were similarly tolerated. Common adverse events included weight gain, somnolence, headache, constipation, and injection-site reactions. Discontinuation for common adverse events was 5%, versus 4% on placebo. The depot uses Medincell's SteadyTeq copolymer. Teva expects U.S. availability in the coming weeks and estimates 2.1 million people in the United States currently diagnosed with schizophrenia. The European Medicines Agency accepted a marketing application in May 2026; it is not approved there.
Links:
Commentary:
The approval changes the dosing interval and the need for post-injection monitoring; the release does not give a PANSS point difference, and Europe has not granted a license.
5. FDA approves Hovilpri (pritelivir) for refractory herpes lesions in immunocompromised adults (Antiviral)
Summary:
Contemporary OB/GYN reported on October 9, citing an FDA release that day, that Hovilpri (pritelivir) tablets are approved for immunocompromised adults with mucocutaneous herpes simplex lesions that did not respond to acyclovir, valacyclovir, or famciclovir. The FDA page says efficacy comes from Part C of phase 3 PRIOH-1 (NCT03073967), a randomized, open-label, comparator-controlled superiority trial. One hundred one immunocompromised adults were randomized and treated with Hovilpri or the investigator's choice of available treatment, for up to 28 days until lesions healed, extendable to 42 days if lesions were improving but not fully healed. Underlying conditions included hematologic malignancy or disorder, hematopoietic stem-cell transplantation, HIV, autoimmune or inflammatory disease, non-hematologic malignancy, or solid-organ transplantation. The primary endpoint was complete healing of all lesions by day 28: 63% with Hovilpri and 34% with the other medicines. The most common adverse reaction was headache. The indication received priority review.
Links:
- FDA — FDA Approves Drug to Treat Lesions Caused by Herpes Simplex Virus
- Contemporary OB/GYN — FDA approves pritelivir tablets to treat lesions from HSV
Commentary:
The 63% versus 34% figure is complete healing by day 28 in an open-label trial of 101 adults, not a cure of the infection and not a result in immunocompetent patients.
6. De novo miniproteins block urinary-pathogen adhesion in mice (Anti-infectives)
Summary:
Nature Communications published an open-access paper on October 9 by David Baker at the University of Washington Institute for Protein Design, Scott J. Hultgren at Washington University in St. Louis, Evgeni V. Sokurenko at the University of Washington, and colleagues. They de novo designed high-affinity miniprotein binders to FimH, an adhesin of uropathogenic Escherichia coli, and to Abp, a chaperone-usher pilus adhesin of Acinetobacter baumannii. The paper says the antagonists are specific and stable, disrupt bacterial recognition of host receptors, block biofilm formation, and are effective for both treatment and prevention in mouse models of uncomplicated and catheter-associated urinary tract infection. Chazin-Gray, Thompson, Lopatto, Hultgren, and Baker are listed as co-inventors on patent application PCT/US26/39298. Hultgren is a cofounder of Fimbrion Therapeutics, which is developing FimH-targeted therapies.
Links:
Commentary:
The paper shows that blocking adhesion works in mouse urinary-infection models, not that a human trial of an antibiotic alternative has started.
III. Basic Research
7. Time-resolved free-electron lasers catch previously unseen intermediates in the penicillin synthase (Structural biology)
Summary:
Nature Catalysis published an open-access paper on October 9 in which Patrick Rabe, Christopher J. Schofield, and colleagues used time-resolved serial femtosecond crystallography and X-ray emission spectroscopy to watch anaerobic isopenicillin N synthase, iron(II), and the tripeptide substrate ACV react with oxygen in microcrystals. The abstract says cysteinyl oxidation produces a thioaldehyde that unexpectedly does not coordinate the iron, and that deuterium-labelled ACV allowed observation of a monocyclic beta-lactam with restoration of the iron-sulfur bond. Mutagenesis, spectroscopy, and computation support iron(IV)-mediated ring formation involving active-site water. The paper reports data at LCLS and PAL-XFEL, with oxygen-exposure time points of 1, 2, 3, 4, 6, 8, and 10 seconds, and uses a primary kinetic isotope effect of about 30 on the deuterated substrate to accumulate the monocyclic intermediate. Phys.org the same day described the collaboration as the University of Oxford with Diamond Light Source, Lawrence Berkeley National Laboratory, PAL-XFEL, and SLAC.
Links:
- Nature Catalysis — Unanticipated intermediates during isopenicillin N synthase catalysis
- Phys.org — Molecular movie reveals how penicillin is made
Commentary:
The structures are single-turnover intermediates inside crystals, not a rewritten synthetic route to a new antibiotic.
8. An IBM superconducting processor uses measurement feedback to restrain quantum chaos on up to 100 qubits (Quantum physics)
Summary:
Nature Physics published a paper on October 9 by Bibek Pokharel, Haining Pan, Jedediah H. Pixley, Maika Takita, and colleagues. The experiments ran on an IBM superconducting quantum processor with up to 100 qubits and implemented a quantum version of the classically chaotic Bernoulli map. The map scrambles quantum information, while local mid-circuit measurements and resets try to steer the dynamics toward a fixed point of the map. That competition drives a dynamical phase transition between quantum and classical dynamics. The paper says the processor applied up to nearly 5,000 entangling gates and 5,000 non-unitary mid-circuit operations on systems of up to 100 qubits and produced accurate estimates of the universal critical properties. Affiliations include IBM Quantum in Yorktown Heights and San Jose, and Rutgers University. The experimental data set is not in a public repository because of its size and is available from the corresponding author on reasonable request.
Links:
Commentary:
What the 100-qubit device shows is a phase transition between feedback and a chaotic map, not a machine that already runs algorithms with fault tolerance.
9. Human, chimpanzee, and gorilla organoids point to morphoregulatory enhancers in human basal radial glia (Development)
Summary:
Nature Communications published an open-access paper on October 9. The corresponding author is Mareike Albert at TU Dresden, with collaborators including Boyan Bonev at Helmholtz Munich, Nereo Kalebic at Human Technopole in Milan, and Madeline A. Lancaster at the MRC Laboratory of Molecular Biology in Cambridge. They compared chromatin accessibility and transcription in neural progenitors from gorilla, chimpanzee, and human cerebral organoids and from human fetal cortex. Organoids were sampled at week 8 and fetal cortex at gestational weeks 13 to 14. Cross-species alignment yielded 225,395 orthologous open-chromatin peaks. In principal-component analysis, cell type accounted for 47% of the variance and species for 24%. Relative to chimpanzee and gorilla, 599 candidate cis-regulatory elements were more accessible in human basal radial glia (log2 fold change at least 1.5, p at most 0.05) and were also open in fetal basal radial glia; they link to 589 target genes. Functional analysis says FAM107A and CNGA3 contribute to the morphological complexity of human basal radial glia. The paper concludes that human-specific morphoregulatory signatures characterize neocortex evolution.
Links:
Commentary:
The enhancers and two genes account for basal-radial-glia shape in organoids, not a measured difference in adult cortical volume.
IV. Climate Assessment
10. IPCC-65 opens in Addis Ababa on October 12, with the working-group timetable still unset (Climate assessment)
Summary:
The IPCC page dates its media advisory to October 9, 2026, with a Geneva dateline of October 8. The 65th plenary meets in Addis Ababa, Ethiopia, from October 12 to 16, hosted by the UN Economic Commission for Africa and Ethiopia. The opening is Monday, October 12, at 16:00 Addis Ababa time (UTC+3) at the Ethiopian Meteorological Institute. IPCC Chair Jim Skea and Ethiopia's Minister of Water and Energy, Habtamu Itefa, will speak, with video messages from the heads of the World Meteorological Organization, the UN Environment Programme, and the UN Framework Convention on Climate Change. Plenary sessions other than the opening are closed to the media. The same page says the Seventh Assessment synthesis report will be released by late 2029, after the three working-group reports. Reuters, carried by The Japan Times on October 9, reports that the 195 member states treat this plenary as a chance to agree publication dates before UN climate talks in November 2028. Working-group chairs propose approving all three reports by September 2028; opponents want the second and third reports pushed into 2029. French co-chair Robert Vautard said the proposal follows the workload, not the summit calendar. The report also says the United States left the IPCC in January and had been its largest funder, and that just over half of the lead authors and editors selected for the next review are from developing or transition economies.
Links:
- IPCC — Sixty-Fifth Session in Addis Ababa, Ethiopia
- The Japan Times — Inside the deadlock at the world's top climate science body
Commentary:
What is public on October 9 is notice of next week's plenary and a report on the timetable dispute, not an adopted publication date for the Seventh Assessment.
Today's Summary
- Cygnus XL left the station at 12:44 p.m. EDT, and the post-release blog sets re-entry for October 12. NASA the same day issued the final commercial-station solicitation, with proposals due December 8 and awards expected in spring 2027.
- The FDA page dates the atezolizumab-plus-chemotherapy adjuvant indication for stage III dMMR colon cancer to October 8, with a disease-free-survival hazard ratio of 0.50; Roche announced it on October 9. The same day Teva's once-monthly subcutaneous olanzapine was approved, and pritelivir completely healed lesions by day 28 in 63% versus 34% of 101 adults.
- Nature Catalysis reports thioaldehyde and monocyclic intermediates in the penicillin synthase. Nature Physics uses measurement feedback against a chaotic map on up to 100 qubits. An organoid paper nominates 599 candidate enhancers in human basal radial glia, and designed miniproteins block adhesion in mouse urinary-infection models.
- IPCC-65 opens in Addis Ababa on October 12. Reuters says the chairs want the three working-group reports approved by September 2028, while opponents want the latter two in 2029. The synthesis report was already described as coming in late 2029.
Daily Framing:
This was a departure-and-approval day: a cargo ship left the station, a monthly injection and an anti-herpes drug entered the FDA record, and the IPCC is still stuck on the Seventh Assessment timetable.
This digest is compiled from real-time search results and is for reference only.